Potentials for the use of glucocorticosteroids in inpatients with severe COVID-19


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Systemic glucocorticosteroids (GCSs) reduce mortality and prevent disease progression in patients with severe new coronavirus infection (COVID-19) and critically ill patients on oxygen support. This has been proven in systematic reviews of clinical trials and is recommended by the guidelines of the WHO, the Ministry of Health of the Russian Federation, and health authorities of foreign countries. Systemic GCSs should only be recommended for patients on oxygen support and should not be recommended for patients who do not require oxygen therapy. We have found insufficient studies comparing GCSs with interleukin-6 receptor inhibitors or Janus kinase inhibitors in order to speak of the superiority of this or that strategY., but in the absence of these biological drugs, GCSs can be considered as an alternative for severe COVID-19 patients on oxygen support.

全文:

受限制的访问

作者简介

Vitaliy Tsvetov

Federal Center for Cardiovascular Surgery

Cand. Sci. (Med.) Chelyabinsk, Russia

A. Matveev

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

K. Mirzaev

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

V. Otdelnov

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

D. Sychev

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

参考

  1. WHO Collaborating Centre for Drug Statistics Methodology [Electronic resource]. 2021. URL: https://www.whocc.no/atc_ddd_index/7code=H02AB&showdescription=no (accessed: 09.07.2021)
  2. Государственный реестр лекарственных средств. Дексаметазон. Инструкция по медицинскому применению (Электронный ресурс)
  3. Государственный реестр лекарственных средств. Преднизолон. Инструкция по медицинскому применению (Электронный ресурс)
  4. Государственный реестр лекарственных средств. Метилпреднизолон. Инструкция по медицинскому применению (Электронный ресурс)
  5. Chousterman B.G., Swirski F.K., Weber G.F. Cytokine storm and sepsis disease pathogenesis. Semin immunopathol. 2017;39(5):517-28. doi: 10.1007/s00281-017-0639-8.
  6. Schwiebert L.M., et al. Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions. J Allergy Clin immunol.
  7. Временные методические рекомендации Министерства здравоохранения РФ по профилактике, диагностике и лечению новой коронавирусной инфекции (COViD-19), версия 11 от 07.05.2021 (Электронный ресурс)
  8. RECOVERY Collaborative Group. N Engl J Med. 2021;384(8):693-704. Doi: 10.1056/ NEJMoa2021436.
  9. Salton F., Confalonieri P., et al. Prolonged Low-Dose Methylprednisolone in Patients With Severe COViD-19 Pneumonia / Open Forum infectious Diseases. 2020;7(issue 10):ofaa421. URL: 10.1093/ofid/ ofaa421.
  10. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COViD-19) Treatment Guidelines. National institutes of Health [Electronic resource]. URL: https://www.covid19treatmentguidelines.nih.gov
  11. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically ill Patients With COViD-19. A Meta-analysis. JAMA. 2020;324(13):1330-41. Doi: 10.1001/ jama.2020.17023.
  12. Pasin L., Navalesi P., Zangrillo A., et al. Corticosteroids for Patients With Coronavirus Disease 2019 (COViD-19) With Different Disease Severity: A Meta-Analysis of Randomized Clinical Trials/Journal of Cardiothoracic and Vascular Anesthesia. Published: 2021-02. Doi: 10.1053/j. jvca.2020.11.057.
  13. Brigham and Women's Hospital COVID-19 Protocols 2021 [Electronic resource]. URL: https://covidprotocols.org/(accessed: 09.07.2021).
  14. Massachusetts General Hospital (MGH) COVID-19 Treatment Guidance 2020. [Electronic resource]. URL: https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/mass- general-COViD-19-treatment-guidance.pdf Version 8.04/28/2021 (accessed: 09.07.2021).
  15. Corticosteroids for COVID-19. Living guidance. WHO ref. number WHO/2019-nCoV/ Corticosteroids/2020.1. URL: https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1 (accessed: 12.07.2021)
  16. Coronavirus disease (COViD-19): Dexamethasone [Electronic resource]. URL: https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid- 19-dexamethasone (accessed: 09.07.2021).
  17. Methylprednisolone for Patients With COViD-19 Severe Acute Respiratory Syndrome (MP-C19) [Electronic resource]. URL: https://clinicaltrials.gov/ct2/show/results/NCT04323592 (accessed: 09.07.2021).
  18. Ma S., Xu C., Liu S., et al. Efficacy and safety of systematic corticosteroids among severe COViD-19 patients: a systematic review and meta-analysis of randomized controlled trials. Sig Transduct Target Ther 6, 83 (2021). doi: 10.1038/s41392-021-00521-7.
  19. Budhathoki P., Shrestha D.B., Rawal E., Khadka S. Corticosteroids in COVID-19: is it Rational7 A Systematic Review and Meta-Analysis [published online ahead of print., 2020 Oct 19]. SN Compr Clin Med. 2020;1-21. doi: 10.1007/s42399-020-00515-6.
  20. van Paassen J., Vos J.S., Hoekstra E.M., et al. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Crit Care. 2020;24:696. Doi: 10.1186/ s13054-020-03400-9.
  21. Wu C., Chen X., Cai Y., et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China [published correction appears in JAMA Intern Med. 2020;180(7):1031]. JAMA Intern Med. 2020;180(7):934-43. doi: 10.1001/jamainternmed.2020.0994.
  22. Cano E.J., Fuentes X.F, Campioli C.C., et al. Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis. Chest. 2021;159(3):1019-40. Doi: 10.1016/j. chest.2020.10.054.
  23. Therapeutics and COVID-19: living guideline. WHO reference number: WHO/2019-nCoV/ therapeutics/2021.2. URL: https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.2 (accessed: 13.07.2021).
  24. Cheng B., Ma J., Yang Y., et al. Systemic Corticosteroid Administration in Coronavirus Disease 2019 Outcomes: An Umbrella Meta-Analysis Incorporating Both Mild and Pulmonary Fibrosis-Manifested Severe Disease. Front. Pharmacol. 2021;12:670170. Doi: 10.3389/ fphar.2021.670170.
  25. Rashad A, Mousa S., Nafady-Hego H., et al. Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab. Sci Rep. 2021;11:8816. doi: 10.1038/s41598-021-88086-x.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2021
##common.cookie##